Haemostatic Changes; Plasma Levels of Alpha2-Antiplasmin-Plasmin Complex and Thrombin-Antithrombin III Complex in Female Breast Cancer

1998 ◽  
Vol 84 (3) ◽  
pp. 364-367 ◽  
Author(s):  
Özgür Özyılkan ◽  
Eşmen Baltalı ◽  
Oktay Özdemir ◽  
Gülten Tekuzman ◽  
Şerafettin Kirazlı ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Plasma Levels ◽  
Antithrombin Iii ◽  
Female Breast Cancer ◽  
Fibrinolytic System ◽  
Coagulation System ◽  
Clotting Factors ◽  
Clotting System ◽  
Thrombin Antithrombin Iii Complex ◽  
Blood Clotting Factors

Aims and background Disorders of hemostasis in patients with malignancies are based on several mechanisms, such as ability of the tumor to alter the coagulation system by producing blood clotting factors or decreasing their inhibitors by increasing fibrinolysis, and by inducing an alteration of blood vessels in relation to the state of local invasion. We investigated the fibrinolytic system marker alpha2-antiplasmin-plasmin complex (APP) and clotting system marker thrombin-antithrombin III complex (TAT) in patients with breast cancer and compare them with CA 15-3, the most well-known breast cancer antigen. Methods Plasma levels of APP and TAT and serum level of CA 15-3 were determined in 57 patients with breast cancer (28 in remission and 29 with active breast cancer) and 13 healthy women. Results In patients with active breast cancer, plasma APP levels were significantly elevated compared to those of other groups (P<0.05). In addition, we observed a poor but positive correlation between plasma levels of APP and those of CA 15-3 (r=0.24; P=0.038). Plasma TAT levels, which reflect the activation of thrombin, were also significantly elevated in patients with active breast cancer (P<0.01), and there was a significant correlation between CA 15-3 and TAT (r=0.24; P=0.041). Conclusions We demonstrated that increased APP and TAT levels might reflect enhanced activation of coagulation and the fibrinolytic system in patients with active breast cancer.

Blood Coagulation Studies and Extracorporeal Circulation in Man

1967 ◽  
Vol 18 (03/04) ◽  
pp. 634-646 ◽  
Author(s):  
N Thurnherr
Keyword(s):  
Blood Coagulation ◽  
Extracorporeal Circulation ◽  
Blood Clotting ◽  
Heart Surgery ◽  
Open Heart Surgery ◽  
Fibrinolytic System ◽  
Open Heart ◽  
Clotting Factors ◽  
Blood Clotting Factors

SummaryBlood clotting investigations have been executed in 25 patients who have undergone open heart surgery with extracorporeal circulation. A description of alterations in the activity of blood clotting factors, the fibrinolytic system, prothrombin consumption and platelets during several phases of the operation is given.

Acute disseminated encephalomyelitis in a boy with elevated plasma levels of thrombin-antithrombin III complex

2001 ◽  
Vol 43 (2) ◽  
pp. 166-168
Author(s):  
Tatsuro Nobutoki ◽  
Takashi Nakano ◽  
Junya Takahashi ◽  
Kazuo Higuchi ◽  
Toshiaki Ihara ◽  
...  
Keyword(s):  
Plasma Levels ◽  
Antithrombin Iii ◽  
Acute Disseminated Encephalomyelitis ◽  
Elevated Plasma ◽  
Thrombin Antithrombin Iii Complex

Haemostatic Activation before and after Surgery in Patients with and without Gastric Malignancy

1994 ◽  
Vol 71 (05) ◽  
pp. 713-718 ◽  
Author(s):  
H B Rahr ◽  
J V Sørensen ◽  
J F Larsen ◽  
F Svendsen Jensen ◽  
C Bredahl ◽  
...  
Keyword(s):  
Plasma Levels ◽  
Malignant Disease ◽  
Antithrombin Iii ◽  
Degradation Products ◽  
Gastric Surgery ◽  
Before And After ◽  
Discharge From Hospital ◽  
Thrombin Antithrombin Iii Complex ◽  
Late Postoperative Period ◽  
Gastric Malignancy

SummaryPre- and postoperative plasma levels of Prothrombin Fragment 1 + 2 (F1+2), Thrombin-antithrombin III complex (TAT), Fibrinopeptide A (FpA), Fibrin and Fibrinogen Degradation Products (FbDP, FgDP) and Soluble Fibrin (SF) were measured in 40 patients undergoing gastric surgery in order to compare patients operated for benign (n = 21) and malignant (n = 19) disease. Plasma levels of F1+2, TAT, FbDP and SF on the first postoperative day were significantly higher than before operation. F1+2 and FbDP levels were further increased one week after surgery, at which time FgDP levels were also higher than preoperatively. A significant postoperative increase in FpA levels was found only in patients with malignant disease. When age was taken into consideration, significant differences between patients with and without malignancy were found only in the late postoperative period, as cancer patients had higher FpA and FbDP levels one week after surgery and higher FbDP levels one month after discharge from hospital.

Increased Plasma Thrombin-Antithrombin III Complex Levels in Non-Insulin Dependent Diabetic Patients with Albuminuria Are Reduced by Ethyl Icosapentatenoate

1995 ◽  
Vol 74 (05) ◽  
pp. 1231-1234 ◽  
Author(s):  
Hiroyuki Shimizu ◽  
Ken-Ichi Ohtani ◽  
Yoshito Tanaka ◽  
Akira Fukatsu ◽  
Yutaka Uehara ◽  
...  
Keyword(s):  
Antithrombin Iii ◽  
Diabetic Patients ◽  
Clotting System ◽  
Urine Albumin ◽  
Group A ◽  
Insulin Dependent ◽  
Group B ◽  
Insulin Dependent Diabetic ◽  
Thrombin Antithrombin Iii Complex ◽  
Niddm Patients

SummaryHypercoagulability may increase the risk of cardiovascular disease (CVD) in diabetic patients with albuminuria. Plasma thrombin-antithrombin III complex (TAT) levels, representing a functional state of clotting system, were studied in one hundred and fifteen non-insulin- dependent diabetic (NIDDM) patients. The patients were divided into three groups according to the urine albumin index (UAI: mg/g Cr): Group A; UAI<30, Group B; 30<UAI<300, Group C; UAI>300. The effect of albuminuria on plasma TAT levels was significant (p<0.02). Ethyl icosapentatenoate (EPA: 1800 mg/day) for 4 weeks significantly (p<0.0005) decreased plasma TAT levels. These data indicate that the degree of diabetic albuminuria is related to plasma TAT levels in NIDDM patients and that treatment with EPA may reduce TAT levels and possibly therefore the rate of development of CVD in patients with NIDDM.

Experimental Thrombocytopenia Induced by Busulphan (Myleran) in Rabbits: Extremely Low Platelet Levels and Intact Plasma Clotting System

1968 ◽  
Vol 19 (03/04) ◽  
pp. 570-577 ◽  
Author(s):  
S. A Evensen ◽  
M Jeremic ◽  
P. F Hjort
Keyword(s):  
Alkylating Agent ◽  
Normal Values ◽  
Coagulation System ◽  
Lag Phase ◽  
Injection Level ◽  
Minimum Level ◽  
Clotting Factors ◽  
Clotting System ◽  
Plasma Coagulation

SummaryThe effects of 2 intraperitoneal injections of the alkylating agent Busulphan (each of 25 mg/kg body weight, 3 days between injections) on the circulating elements of the blood and on the plasma coagulation system in rabbits have been investigated.Platelets fell progressively after a lag-phase of 7 days, reached a mean minimum level of about 3 % of the pre-injection level in 14 days, and then returned slowly towards normal values. Bleeding was an occasional complication and a rare cause of death. Granulocytopenia developed synchronously with the fall in platelets. The plasma clotting factors remained intact.We conclude that this is a useful experimental model for studies on the role of platelets in hemostasis and thrombosis.

Haemostatic Studies in Carbohydrate-deficient Glycoprotein Syndrome Type I

1996 ◽  
Vol 76 (04) ◽  
pp. 502-504 ◽  
Author(s):  
A Fiumara ◽  
R Barone ◽  
P Buttitta ◽  
R Musso ◽  
L Pavone ◽  
...  
Keyword(s):  
Plasma Levels ◽  
Protein C ◽  
Antithrombin Iii ◽  
Plasma Concentrations ◽  
Protein S ◽  
Coagulation Factors ◽  
Type I ◽  
Clotting Factors ◽  
Blood Coagulation Factors ◽  
D Dimer

SummaryCDG syndrome (CDGS) type I is the most frequent form of a group of metabolic disorders characterised by a defect of the carbohydrate moiety of glycoproteins. A large number of plasma glycoproteins, including clotting factors and inhibitors, are decreased and stroke-like episodes have been described in about half of the reported patients. We studied blood coagulation factors, inhibitors and D-dimer plasma levels in four subjects, aged 12-23 years, with CDGS type I. Factors VIII, XI, antithrombin III activity, antigen plasma levels of antithrombin III, free protein S and protein C were decreased whereas protein C as activity was normal. In addition two patients had reduction of factors II, V, VII, IX, X reflecting the phenotypic heterogeneity associated with CDGS type I. D-dimer plasma concentrations were elevated in all subjects. The hypercoagulable state as consequence of the combined deficiencies of coagulation inhibitors could contribute to the stroke-like phenomena in CDGS type I.

scholarly journals Interleukin-10 Inhibits Activation of Coagulation and Fibrinolysis During Human Endotoxemia

Blood ◽  
1997 ◽  
Vol 89 (8) ◽  
pp. 2701-2705 ◽  
Author(s):  
Dasja Pajkrt ◽  
Tom van der Poll ◽  
Marcel Levi ◽  
David L. Cutler ◽  
Melton B. Affrime ◽  
...  
Keyword(s):  
Plasminogen Activator ◽  
Plasma Levels ◽  
Plasma Concentrations ◽  
Interleukin 10 ◽  
Fibrinolytic System ◽  
Tissue Type ◽  
Coagulation System ◽  
Plasminogen Activator Inhibitor 1 ◽  
Human Endotoxemia ◽  
Lps Challenge

Abstract Interleukin-10 (IL-10) has been found to inhibit lipopolysaccharide (LPS)-induced tissue factor expression by monocytes in vitro. To determine the effects of IL-10 on LPS-induced activation of the hemostatic mechanisms in vivo, we performed a placebo-controlled, cross-over study of human endotoxemia. Two groups of eight volunteers were challenged with LPS (4 ng/kg) on two occasions: once in conjunction with placebo, and once with recombinant human IL-10 (rhIL-10; 25 μg/kg). In group 1, placebo or rhIL-10 was given 2 minutes before LPS challenge, group 2 received placebo or rhIL-10 1 hour after LPS administration. Pretreatment with rhIL-10 reduced both LPS-induced activation of the fibrinolytic system (plasma concentrations of tissue type plasminogen activator, plasmin-α2–antiplasmin complexes, and D-dimer), and inhibition of fibrinolysis (plasma levels of plasminogen activator inhibitor 1), whereas posttreatment only inhibited the latter response. Both IL-10 pre- and posttreatment attenuated activation of the coagulation system (plasma levels of prothrombin fragment F1 + 2 and thrombin–antithrombin complexes). These results indicate that rhIL-10, besides its well-described inhibitory effects on cytokine release, potently modulates the fibrinolytic system and inhibits the coagulant responses during endotoxemia.

Sign in / Sign up

Export Citation Format

Share Document